Glycogen synthase kinase 3 (GSK-3) is a multifunctional serine/threonine kinase that has two isoforms, alpha and beta. It controls the receptor tyrosine kinase, cytokine, and Wnt signaling pathways negatively and is highly conserved. Inhibiting GSK-3 through the stimulation of these pathways affects a variety of downstream effectors, such as transcription factors, nutrient sensors, glycogen synthesis, mitochondrial function, circadian rhythm, and cell fate. In response to T-cell receptor activation, GSK-3 also controls alternative splicing, and current phosphoproteomic studies have shown that numerous splicing regulators and splicing factors are phosphorylated in a GSK-3-dependent manner.
Alzheimer's disease (AD) and other neurodegenerative pathologies, as well as other types of diseases like diabetes, cardiovascular problems, and cancer, are caused by the dysfunction or abnormal activity of GSK-3. GSK-3 is a prime candidate for therapeutic intervention because it is also connected to innate immune defense against pathogens.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V0224 | 1-Azakenpaullone (1-Akp) | 676596-65-9 | 1-Azakenpaullone(1-Akp), an analog of kenpaullone, is a novel, ATP-competitive and selective inhibitor of GSK-3β (glycogen synthase kinase 3β) with potentialantidiabetic and neuroprotective activities. |
|
V0228 | BIO-acetoxime (GSK-3 Inhibitor X; BIA) | 667463-85-6 | BIO-acetoxime (also known asGSK-3 Inhibitor X;BIA),a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, is a novel, potent and selective dual inhibitor of GSK3α/β (glycogen synthase kinase-3) with potentialanti-infection andanticonvulsant as well as anticancereffects. |
|
V9740 | 9-ING-41 | 1034895-42-5 | 9-ING-41 is a glycogen synthase kinase-3 (GSK-3) inhibitor that induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. |
|
V0220 | AZD1080 | 612487-72-6 | AZD1080 is a selective, potent,orally bioactive, and brain permeable GSK3 (glycogen synthase kinase-3) inhibitor with neuroprotective effects. |
|
V0219 | AZD2858 | 486424-20-8 | AZD2858 is a novel, potent, orally bioactive, and selective GSK-3 (glycogen synthase kinase-3) inhibitor with the potential to be used in fracture healing. |
|
V37593 | BRD0705 | 2056261-41-5 | BRD0705 is a novel, potent,paralog selectiveand orally bioactive glycogen synthase kinase 3α (GSK3α) inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. |
|
V4053 | BRD5648 | 2056261-42-6 | BRD-5648 (also known as (R)-BRD-0705) is an inactive (R)-enantiomer of BRD-0705. |
|
V0213 | CHIR-98014 | 252935-94-7 | CHIR-98014 (also known as CT-98024) is a novel, potent, reversible, cell-permeable inhibitor of GSK-3 (glycogen synthase kinase-3) with potential anti-diabetic activity. |
|
V3531 | GSK-3 inhibitor 1 | 603272-51-1 | GSK-3 inhibitor 1 is a novel and potent inhibitor ofGSK-3 (Glycogen synthase kinase-3). |
|
V0221 | AR-A014418 (SN-4521; GSK 3β inhibitor VIII) | 487021-52-3 | AR-A014418 (AR 0133418; SN4521; GSK-3β inhibitor VIII; AR 014418) is a novel, potent, ATP-competitive, and selective inhibitor of GSK3β (Glycogen Synthase Kinase 3β) with the potential for neurodegenerative diseases. |
|
V0226 | IM-12 | 1129669-05-1 | IM-12, anindolylmaleimide analog, is a novel, potent, cell-permeable and selective inhibitor of GSK-3β (glycogen synthase kinase-3β) withpotential neuroprotective effects. |
|
V2448 | KY19382 | 2226664-93-1 | KY-19382 is a novel, potent and orally active dual inhibitor of CXXC5-DVL( IC50s =19)and GSK3β( IC50s = 10 nM). |
|
V3821 | Laduviglusib (CHIR99021) trihydrochloride | 1782235-14-6 | Laduviglusib (CHIR99021; CHIR-99021) 3HCl, the trihydrochloride salt form of CHIR-99021 (also called CT99021 or CHIR-911), is a potent and orally bioavailable GSK-3α/β (glycogen synthase kinase 3α/β) inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; CHIR-99021 was proved to promote self-renewal and maintain pluripotency of both B6 and BALB/c ES cells via stabilizing the downstream effectors like c-Myc and β -catenin. |
|
V0223 | LY2090314 | 603288-22-8 | LY2090314 (LY-2090314) is a novel and potent GSK-3 (glycogen synthase kinase-3) inhibitor for GSK-3α/β with potential antitumor activity. |
|
V0212 | SB216763 | 280744-09-4 | SB216763 is a novel, potent and selective GSK-3 (glycogen synthase kinase-3) inhibitor with anti-inflammatory activiity and neuro-protective effects as it canpromote DNA repair in ischemic retinal neurons. |
|
V0216 | SB415286 | 264218-23-7 | SB415286 is a novel, potent,selective, cell permeable and ATP-competitive GSK3α (glycogen synthase kinase-3alpha) inhibitor with potential anti-inflammatory activity. |
|
V0222 | TDZD-8 (NP-01139) | 327036-89-5 | TDZD-8(NP01139; GSK3 Inhibitor I) is a novel, potent and non-ATP competitive GSK-3β (glycogen synthase kinase-3beta) inhibitor with the potential for treating neurodegenerative diseases such as PD (parkinson disease). |
|
V0214 | TWS119 | 601514-19-6 | TWS119, apyrrolopyrimidine compound, is a novel, potent and selective/specific GSK-3β (Glycogen synthase kinase-3β) inhibitor with potentialusefulness for in vivo stem cell biology and therapy. |
|
V0211 | Laduviglusib (CHIR99021) | 252917-06-9 | Laduviglusib (CHIR-99021; CT99021; CT 99021) is a novel, potent and orally bioavailable inhibitor of GSK-3α/β (glycogen synthase kinase 3α/β) with the potential to treattype 2 diabetes. |
|
V2805 | Laduviglusib (CHIR-99021; CT99021) HCl | 1797989-42-4 | Laduviglusib (CHIR-99021; CT99021 or CHIR-911) HCl is the hydrochloride salt of CHIR-99021, which is a potent and orally available GSK-3α/β (glycogen synthase kinase 3α/β) inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; CHIR-99021 was proved to promote self-renewal and maintain pluripotency of both B6 and BALB/c ES cells via stabilizing the downstream effectors like c-Myc and β -catenin. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
